In a collaboration between several labs at UNC Lineberger, researchers have defined cancer-associated fibroblast (CAF) subtypes that are clinically robust, prognostic, and predictive of immunotherapy response and developed a clinical classifier designed to distinguish between these subtypes in patients.
This article was originally published on MedicalXpress.com

